1085539-03-2

Usage

Uses

Used in Pharmaceutical Industry:
(2-bromo-5-methylphenyl)acetonitrile is used as an intermediate in the synthesis of various organic compounds for the development of pharmaceutical drugs. Its unique structure allows for the creation of new drug candidates with potential therapeutic applications.
Used in Agricultural Industry:
In the agricultural sector, (2-bromo-5-methylphenyl)acetonitrile serves as a building block for the preparation of certain agrochemicals. Its properties can be utilized to develop new pesticides or herbicides to improve crop protection and yield.
Used in Material Science:
(2-bromo-5-methylphenyl)acetonitrile is used as a starting material in the production of specialty polymers and other materials. Its chemical reactivity and structure contribute to the development of advanced materials with specific properties for various applications.
It is important to handle (2-bromo-5-methylphenyl)acetonitrile with care due to potential hazards associated with its use and handling. Proper safety measures should be taken to ensure the safe utilization of (2-bromo-5-methylphenyl)acetonitrile in different industries.

Upstream product

• 773837-37-9 sodium cyanide 
• 1085539-05-4 C₉H₁₁BrO₃S 
• 27561-50-8 1-bromo-2-(bromomethyl)-4-methylbenzene 

Downstream Products

• 203314-29-8 2-bromo-5-methylphenylacetic acid 
• 1273546-85-2 N-Boc-N-[2-(2-bromo-5-methyl-phenyl)ethyl]amine 
• 1198271-99-6 (3S)-(E)-N-Boc-N-[2-[2-(3-hydroxybut-1-enyl)-5-methylphenyl]ethyl]amine 
• 1273546-97-6 (3S)-(E)-N-Boc-[2-[2-(3-tert-butyldimethylsilyloxy-1-butenyl)-5-methylphenyl]ethyl]amine 
• 1085539-04-3 2-(2-bromo-5-methylphenyl)ethaneamine hydrochloride 

Relevant academic research and scientific papers

Chiral Magnesium Bisphosphate-Catalyzed Asymmetric Double C(sp3)-H Bond Functionalization Based on Sequential Hydride Shift/Cyclization Process

Described herein is a chiral magnesium bisphosphate-catalyzed asymmetric double C(sp3)-H bond functionalization triggered by a sequential hydride shift/cyclization process. This reaction consists of stereoselective domino C(sp3)-H bond functionalization: (1) a highly enantio- and diastereoselective C(sp3)-H bond functionalization by chiral magnesium bisphosphate (first [1,5]-hydride shift), and (2) a highly diastereoselective C(sp3)-H bond functionalization by an achiral catalyst (Yb(OTf)3, second [1,5]-hydride shift).

1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND

Provided is a compound useful as an N-type Ca2+ channel blocker. As a result of intensive studies of compounds having an action of blocking N-type Ca2+ channels, the present inventors found that a tetrahydroisoquinoline compound of the present invention having a substituent at the 1-position has an action of blocking the N-type Ca2+ channels, an antinociceptive pain action, an antineuropathic pain action, an abdominal pain-inhibitory action and an opioid-induced constipation-improving action, and the present invention has been completed based on these findings. The compound of the present invention can be used as a pharmaceutical composition for preventing and/or treating various pains such as neuropathic pain and nociceptive pain, headaches such as migraine and cluster headache, central nervous system diseases such as anxiety, depression, epilepsy, cerebral stroke and restless legs syndrome, abdominal symptoms such as abdominal pain and abdominal distension, stool abnormalities such as diarrhea and constipation, digestive system diseases such as irritable bowel syndrome, urinary system diseases such as overactive bladder and interstitial cystitis, etc.